The management of sepsis: A practical review

Journal of Intensive Care Medicine

Volumn 13, Issue 5, 1998, Pages 229-240

  Marik, Paul E ^a,c   Varon, Joseph ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c SAINT VINCENT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HETASTARCH;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY TRACT DISEASE; ANTIBIOTIC THERAPY; DIAGNOSTIC APPROACH ROUTE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMODYNAMIC MONITORING; HUMAN; IMMUNOMODULATION; OLIGURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT OUTCOME;

EID: 0031720917     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1489.1998.00229.x     Document Type: Review

References (186)

1. Bone RC. Sepsis, the sepsis syndrome, multiorgan failure: a plea for comparable definitions. Ann Intern Med 1991;114:332-333
2. Dellinger RP, Zimmerman JL. Gram-negative sepsis. Hosp Pharm 1991;26:592-599
3. Kreger E, Craven D, McCabe W. Gram-negative bacteremia. IV. Reevaluation of clinical features and treatment in 612 patients. Am J Med 1980;68:344-355
4. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 1990;39:31-34
5. Abraham E, Wunderink R, Silverman H, Pere TM, Nasraway S, Levy H. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995;273:934-941
6. Parrillo JE, Parker MM, Natanson C. Septic shock in humans: advances in understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990;113:227-242
7. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5
8. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 1996;24:1431-1440
9. Fein AM, Bernard GR, Criner GJ, el al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127). JAMA 1997;277:482-487
10. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918
11. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-1100
12. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997;277:1531-1538
13. Abraham E. Effect of a murine monoclonal antibody (TNF-mAB) in patients with septic shock [abstract]. Proceedings of the International Conference of Chemotherapy. Sydney, Australia, 1997.
14. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-469
15. Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874
16. Bone RC. The sepsis syndrome: definition and general approach to management. In: Dorinsky PM, ed. Clinics of Chest Medicine. Philadelphia: WB Saunders, 1996:175-182
17. Hazinski MF, Iberti TJ, MacIntyre NR, Parker MM, Prion S, Chemel H. Epidemiology, pathophysiology and clinical presentaion of gram-negative sepsis. Am J Crit Care 1993;2:224-235
18. Centers for Disease Control and Prevention. Annual summary of births, marriages, divorces and deaths. United States, 1993. MVSR 1994;42:4-10
19. Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 1996;24:1072-1078
20. Pajkrt D, van Deventer SJ. The cellular response in sepsis. Curr Top Microbiol Immunol 1996;216:119-132
21. Hayashi S, Gillian IC, Bondy G, Duronio V, Hogg JC. Molecular mechanisms of sepsis: molecular biology of the cell. J Crit Care 1997;10:82-95
22. Marsh CB, Wewers MD. The pathogenesis of sepsis: factors that modulate the response to gram-negative bacterial infection. In: Dorinsky PM, ed. Clinical Chest Medicine. Philadelphia: WB Saunders, 1996:183-198
23. American Medical Association. Office of Quality Assurance and Health Care Organizations' attributes to guidelines development of practice parameters. Chicago: American Medical Association, 1990.
24. Rackow EC, Astiz ME. Pathophysiology and treatment of septic shock. JAMA 1991;266:548-554
25. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-1843
26. Clinical bacteriology. In: Hutchison R, Rainy H, eds. Clinical methods: a guide to the practical study of medicine, 6th ed. London: Cassell and Company, 1918:590-628
27. Schein M, Hirshber A, Hashmonai M. Current surgical management of severe intra-abdominal infection. Surgery 1992;112:489-496
28. Levinson MA, Zeigler D. Correlation of APACHE II score, drainage technique and outcome in postoperative intra-abdominal abscess. Surg Gynecol Obstet 1991;172:89-94
29. Eyer S, Brummitt C, Crossley K, Siegel R, Cerra FB. Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med 1990;18:1073-1079
30. Pearson ML. Guidelines for the prevention of intravascular device related infections. Infect Control Hosp Epidemiol 1996;17:438-473
31. Cunha BA. Antibiotic treatment of sepsis. Med Clin N Am 1995;79:551-558
32. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991;28:753-764
33. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patiens with serious infections. Lancet 1993;341:335-339
34. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-2583
35. Marik PE. The failure of a once-daily vancomycin dosing regimen in patients with normal renal function. J Antimicrob Chemother 1997;40:745-746
36. Moellering R. Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:199-212
37. Marik PE. Gastric intramucosal pH. A better predictor of multiorgan dysfunction syndrome and death than oxygen-derived variables in patients with sepsis. Chest 1993;104:225-229
38. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992;102:216-220
39. Edwards JD, Brown GCS, Nightingale P, Slater RM. Use of survivors cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med 1989;17:1098-1013
40. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477
41. Chernow B, Rainey TR, Lake CR. Endogenous and exogenous catecholamines in critical care medicine. Crit Care Med 1982;10:409-416
42. Hollenberg SM, Cunnion RE. Endothelial and vascular smooth muscle function in sepsis. J Crit Care 1994;9:262-280
43. Hollenberg SM, Tangora JJ, Piotrowski MJ, Easington C, Parrillo JE. Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 1997;25:869-873
44. Fink MP. Adequacy of gut oxygenation in endotoxemia and sepsis. Crit Care Med 1993;21:S4-S8
45. Thijs LG. Peripheral circulation in human septic shock. Intensive Crit Care Digest 1988;7:9-11
46. Sibbald WJ, Fox G, Martin CM. Abnormalities of vascular reactivity in sepsis syndrome. Chest 1991;100(suppl):S155-S159
47. Smith LW, Winbery SL, Barker LA, McDonough KH. Cardiac-function and chronotropic sensitivity to beta-adrenergic stimulation is sepsis. Am J Physiol 1986;251:H405-H412
48. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE. Depressed left ventricular performance: response to volume infusion in patients with sepsis and septic shock. Chest 1988;93:903-910
49. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parrillo JE. Response of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 1989;4:19-25
50. Brunnell E, Parrillo JE. Cardiac dysfunction during septic shock. Clin Chest Med 1996;17:237-248
51. Cowan BN, Burns HJG, Boyle P, Ledingham IMA. The relative prognostic value of lactate and hemodynamic measurement in early shock. Anaesthesia 1984;39:750-755
52. Tuchschmidt J, Fried J, Swinney R, Sharma OM. Early hemo-dynamic correlates of survival in patients with septic shock. Crit Care Med 1989;17:719-723
53. Maynard N, Bihari D, Beale R, Smithies M, Baldock G, Mason R. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 1993;270:1203-1210
54. Ognibene FP. Hemodynamic support during sepsis. Clin Chest Med 1996;17:279-287
55. Bollaert PE, Bauer P, Audibert G, Lambert H, Larcan A. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 1990;98:949-953
56. Flancbaum L, Dick M, Dasta J, Choban P. A dose-response study of phenylephrine in critically ill, septic surgical patients. Eur J Clin Pharmacol 1997;51:461-465
57. Falk JL, Rackow EC, Astiz ME, Weil MH. Effects of hetastarch and albumin on coagulation in patients with septic shock. J Clin Pharmacol 1988;28:412-415
58. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996;276:889-897
59. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-1357
60. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826-1831
61. Diebel L, Wilson RF, Heins J, Larky H, Warsow K, Wilson S. End-diastolic volume versus pulmonary artery wedge pressure in evaluating cardiac preload in trauma patients. J Trauma 1994;37:950-955
62. Reuse C, Vincent JL, Pinsky MR. Measurements of right ventricular volumes during fluid challenge. Chest 1990;98:1450-1454
63. Shippy CR, Appel PL, Shoemaker WC. Reliability of clinical monitoring to assess blood volume in critically ill patients. Crit Care Med 1984;12:107-112
64. Rackow EC, Falk JL, Fein A, et al. Fluid resuscitation in circulatory shock: a comparison, of the cardiorespiratory effects of albumin, hetastarch, and saline infusions in patients with hypovolemic and septic shock. Crit Care Med 1983;11:839-850
65. Marik PE, Iglesias J, Maini B. Gastric intramucosal pH changes after volume replacement with hydroxyethyl starch or crystalloid in patients undergoing elective abdominal aortic aneurysm repair. J Intensive Care Med 1997;12:51-55
66. Zikria BA, King TC, Stanford J. A biophysical approach to capillary permeability. Surgery 1989;105:625-631
67. Boldt J, Muller M, Heesen M. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 1996;24:385-391
68. Boldt J, Heesen M, Padberg W, Martin K, Hempelmann G. The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Anaesthesia 1996;51:529-535
69. Boldt J, Mueller M, Menges T, Papsdorf M, Hempelmann G. Influence of different volume therapy regimens on regulators of the circulation in the critically ill. Br J Anaesth 1996;77:480-487
70. Boldt J, Heesen M, Muller M, Pabsdorf M, Hempelmann G. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg 1996;83:254-261
71. Morisaki J, Bloos F, Neal A. Colloid infusion preserves micro-vascular integrity better than crystalloid in hyperdynamic sepsis. Crit Care Med 1992;20(suppl):S101
72. Hakaim AG, Corsetti R. The pentafraction of hydroxyethyl starch inhibits ischemia-induced compartment syndrome. J Trauma 1994;37:18-21
73. Myers GA, Conhaim RL, Rosenfeld DJ, Harms BA. Effects of pentafraction and hetastarch plasma expansion on lung and soft tissue transvascular fluid filtration. Surgery 1995;117:340-349
74. Oz MC, Fitz Patrick MF, Zikria BA, Pinsky DJ, Duran WN. Attenuation of microvascular permeability dysfunction in postischemic striated muscle by hydroxyethyl starch. Microvase Res 1995;50:71-79
75. Krieger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980;68:344-355
76. Fry DE. Multiple system organ failure. Surg Clin N Am 1988;68:107-122
77. Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: how to detect, how to correct, how to prevent? Am J Respir Crit Care Med 1996;154:1573-1578
78. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996;24:525-537
79. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemo-dynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized, study. Intensive Care Med 1997;23:282-287
80. Schreuder WO, Schneider AJ, Groenveld ABJ, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock: emphasis on right ventricular performance. Chest 1989;95:1282-1288
81. Segal JM, Phang PT, Walley KR. Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992;73:1159-1164
82. Giraud GD, MacCannell KL. Decreased nutrient blood flow during dopamine- and epinephrine-induced intestinal vasodilation. J Pharmacol Exp Ther 1984;30:214-220
83. Neviere R, Mathieu D, Chagnon JL, Lehleu N, Wattel F. The-contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 1996;154:1684-1688
84. Olson D, Pohlman A, Hall JB. Administration of low-dose dopamine to non-oliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance. Am J Respir Crit Care Med 1996;154:1664-1670
85. Van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996;24:1580-1590
86. Duranteau J, Sitbon P, Teboul JL, et al. Compared effects of epinephrine, norepinephrine, norepinephrine-dobutamine on the gastric mucosal blood flow in patients with septic shock [abstract]. Am J Respir Crit Care Med 1996;153:A832
87. Diaz-Cremades JM, Lorenzo R, Sanchez M, Moreno MJ, Alsar MJ, Bosch JM. The use of ATIII in critically ill patients. Intensive Care Med 1994;20:577-580
88. Silverman HJ, Tuma P. Gastric tonometry in patients with sepsis: effects of dobutamine infusions and packed red blood cell transfusions. Chest 1992;102:184-188
89. Duke GJ, Briedis J, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine. Crit Care Med 1994;22:1919-1925
90. Desjars P, Pinaud M, Bugnon D, Tassea F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989;17:426-429
91. Mackenzie S, Kapadia F, Immo G, Armstrong I, Grant I. Adrenaline in the treatment of septic shock: effects on hemo-dynamics and oxygen transport. Intensive Care Med 1991;17:36-39
92. Day NP, Phu NH, Bethell DP, Mai NTH, Chau TTH, Hien TT. The effects of dopamine and adrenaline infusions on acid-base balance and systemic hemodynamics in severe infection. Lancet 1996;348:219-223
93. Wilson W, Lipman J, Scribante J. Septic shock: does adrenaline have a role as a first line inotropic agent? Anaesth Intensive Care 1992;20:470-474
94. Yamazaki T, Shimada Y, Taenaka N, Oshumi H, Takezawa J, Yoshiya I. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med 1982;10:432-435
95. 2 adrenoceptors. Br J Pharmacol 1985;85:599-608
96. Maynard N, Bihari DJ, Dalton RN, Smithies MN, Mason RC. Increasing splanchnic blood flow in the critically ill. Chest 1995;108:1648-1654
97. Prielipp RC, MacGregor DA, Butterworth JF, et al. Pharmaco-dynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Chest 1996;109:1291-1301
98. Brackett DJ, Schaefer CF, Tompkins P. Evaluation of cardiac output, total peripheral resistance, and plasma concentrations of vasopressin in the unrestrained rat during endotoxemia. Circ Shock 1985;17:273-284
99. Raid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation 1997;95:1108-1110
100. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282
101. Nathan C, Xie Q-W. Nitric oxide synthetases: roles, tolls, controls. Cell 1994;78:915-918
102. Gibaldi M. What is nitric oxide and why are so many people studying it? J Clin Pharmacol 1993;33:488-496
103. Rossaint R. Nitric oxide: a new area in intensive care. Presse Med 1994;23:855-858
104. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res 1994;74:1121-1125
105. Lorente JA, De Pablo R, Renes E, Liste D. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993;21:1287-1295
106. Payen D, Bernard C, Beloucif S. Nitric oxide in sepsis. Clin Chest Med 1996;17:333-350
107. Petros A, Lamb G, Leone A, Moncada S. Bennett D, Vallance P. Effect of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-39
108. Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995;21:1027-1031
109. Hollenberg SM, Piotrowski MJ, Parrillo JE. Nitric oxide synthetase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993;264: H660-H663
110. Jourdain M, Tournoys A, Leroy X, et al. Effects of N-nitro-L-arginine methy ester on the endotoxin-induced disseminated intravascular coagulation in porcine septic shock. Crit Care Med 1997;25:452-459
111. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 1994;180:1153-1158
112. Liew FY. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol 1995:7:396-399
113. Liew FY, Cox FEG. Nonspecific defence mechanisms: the role of nitric oxide. Immunol Today 1991;12:A17-A21
114. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adherence. Proc Natl Acad Sci USA 1991;88:4651-4655
115. Cook DJ, Guyatt GH, Reeve BK. The predictive value of serum cortisol in septic shock. J Intensive Care Med 1991;6:84-89
116. Schein RMH, Sprung CL, Marcial E. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990;18:259-263
117. Jurney TH, Cockrell JL, Lindberg JS, Lamiell JM, Wade WE. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987;92:292-295
118. Soni A, Pepper GM, Wyrwinski PM, Ramirez NE, Simon R, Pina T. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-271
119. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients. Chest 1988;94:1176-1186
120. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effects of deliberate perioperative increase of oxygen delivery on mortality in high risk surgical patients. JAMA 1993;270:2699-2707
121. Hayes M, Timmins AC, Yau E, Palazzo M, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;30:1717-1722
122. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025-1032
123. Gutierrez G, Brown S. Gastric tonometry: a new monitoring modality in the intensive care unit. J Intensive Care Med 1995;10:34-44
124. Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. Crit Care Med 1995;23:1184-1193
125. Gutierrez G, Palizas F, Doglio G, Wainsztein N, Gallesio A, Pacin J. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992;339:195-199
126. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJM. Acute renal failure in intensive care units-causes, outcome and prognostic factors of hospital mortality: a prospective, multicenter study. Crit Care Med 1996;24:192-198
127. Groeneveld ABJ, Tra DD, Van der Meulen J. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron 1991;59:602-610
128. Chertow G, Sayegh M, Allgren RL. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure. Am J Med 1996;101:49-53
129. Bersten A, Rutten A. Renovascular interaction of epinephrine, dopamine, and intraperitoneal sepsis. Crit Care Med 1995;23:537-544
130. Leblanc M, Tapolyai M, Paganini EP. What dialysis dose should be provided in acute renal failure? A review. Adv Ren Replace Ther 1995;2:255-264
131. Clark WR, Mueller BA, Alaka KJ. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994;4:1413-1420
132. Leblanc M, Bonardeaux A, Cardinal J. Kt/V in continuous dialysis techniques. Semin Dialys 1995;8:51-52
133. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993;21:328-338
134. Geronomus R, Schneider L, Miale A. Middle molecule clearance in continuous arteriovenous hemodialysis. Kidney Int 1987;31:232
135. Barrera P, Janssen EM, Demacker PN. Removal of interleukin-1 and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes. Lymphokine Res 1992;11:99-104
136. Bellemo R, Tipping P, Boyce N. Continuous veno-veno hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-526
137. Vincent JL, Tielemans C. Continuous hemofiltration in severe sepsis: is it beneficial? J Crit Care 1995;10:27-32
138. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995;332:27-34
139. Schuster DP, Kollef MH. Acute respiratory distress syndrome. Dis Mon 1996;42:265-328
140. Niederman FS, Fein AM. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin Chest Med 1990;11:633-656
141. Lechin AE, Varon J. Adult respiratory distress syndrome (ARDS): the basics. J Emerg Med 1994;12:63-68
142. Slutsky AS. ACCP consensus conference: mechanical ventilation. Chest 1993;104:1833-1859
143. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhihitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995;23:1835-1842
144. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithromhin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
145. Bick RL. Disseminated intravascular coagulation. Hematol Oncol Clin N Am 1992;6:1259-1285
146. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 1989;15:347-352
147. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (ATIII) and TRP 49-modified AT III on plasma level of 6-keto-PGF1-α in rats. Thromb Res 1995;80:201-208
148. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888
149. Busund R, Straume B, Revhaug A. Fatal course in severe meningocoecemia: clinical predictors and effects of transfusion therapy. Crit Care Med 1993;21:1699-1705
150. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993;269:3024-3029
151. George CD, Morello PJ. Immunologic effect of blood transfusion upon renal transplantation, tumor operations and bacterial infections. Am J Surg 1986;152:329-337
152. Naetani S, Nishikawa T, Tobe T, Hirakawa A. Role of blood transfusion in organ failure following major abdominal surgery. Ann Surg 1986;203:275-282
153. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomized comparison of leucocyte-depleted versus buffy-coat-poor transfusion and complications after colorectal surgery. Lancet 1996;348:841-845
154. Hebert PC, Wells G, Marshall J, Martin C, Tweeddale M, Pagliarello G. Transfusion requirements in critical care. JAMA 1995;273:1439-1444
155. Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995;23:436-449
156. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14:436-441
157. Saatcioglu F, Claret FX, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994;5:347-359
158. Barnes PJ, Karin M. Nuclear factor-kB-A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071
159. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012
160. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10(suppl 2):81-90
161. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of phospholipase A2 inhibitor which prevent prostaglandin generation. Nature 1979;278:456-459
162. Hammerschmidt DE, White JG, Graddock PR. Corticosteroids inhibit complement-induced granulocyte aggregation: a possible mechanism for their efficacy in shock states. J Clin Invest 1979;63:798-803
163. Packard BD, Weiler JM. Steroids inhibit activation of the alternative amplification pathway of complement. Infect Immunol 1983;40:1011-1019
164. Hahn EO, Houser HB, Rammelkamp CH. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest 1951;30:274-281
165. Cronin L, Cook DJ, Carlet J. Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-1439
166. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-1303
167. McCabe W, Greely A. Immunization with R mutants of Salmonella minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972;108:601-610
168. Ziegler EJ, McCutcha JA, Fierer J, Glauser MP, Sadoff JC, Douglas H. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-1230
169. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sandoff JC, Foulke GE. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-436
170. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097-1102
171. Wenzel R, Bone RC, Fein A, Quenzer R, Shentag J, Gorelick KJ. Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis [abstract]. Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago, 1991;294.
172. Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 1988;158:312-319
173. Sadoff J. Soluble TNF receptors. Proceedings of the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches, Munich, Germany, 1994.
174. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1990;334:1697-1702
175. Boekstegers P, Weidenhofer S, Zell R, Holler E, Ertel W. Repeated administration of aF(ab)2 fragment of anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects of the cardiovascular system and cytokines levels. Shock 1994;1:237-245
176. Opal SM, Fisher CJ, Dhainaut JFA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-1124
177. Dhainaut JF, Tenaillon A, Le TY, Schlemmer B, Solet JP. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720-1728
178. Dhainaut JF, Tenaillon A, Hemmer M. Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe gram-negative sepsis [abstract]. Am J Respir Crit Care Med 1995;151:A447
179. Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995;20:143-158
180. Liu M, Slutsky AS. Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Intensive Care Med 1997;23:718-731
181. Austin OM, Redmond HP, Watson WG, Cuney RJ, Grace PA, Bouchier-Hayes D. The beneficial effects of immunostimulation in posttraumatic sepsis. J Surg Res 1995;59:446-449
182. Dale DC, Liles WC, Summer WR, Nelson S. Review: Granulocyte colony stimulating factor - role and relationship in infectious diseases. J Infect Dis 1995;172:1061-1075
183. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997;15:1163-1170
184. Hartug T, Docke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995;85:2482-2489
185. Pollmacher T, Korth C, Mullington J. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87:900-905
186. Nelson S, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H. Filgrastim in the treatment of hospitalized patients with community acquired pneumonia (CAP). Am J Respir Crit Care Med 1996;153:A535